Lorenzo Falchi, MD, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial trial evaluating the subcutaneous administration of epcoritamab with R-CHOP in patients with high-risk diffuse large B-cell lymphoma.
Lorenzo Falchi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial (NCT04663347) trial evaluating the subcutaneous administration of epcoritamab with R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with high-risk diffuse large B-cell lymphoma (DLBCL).
The study has enrolled 33 patients and recruitment is ongoing, Falchi says. The patient population comprises those with classic, high-risk DLBCL, with 24% of patients presenting with aggressive lymphoma subtypes, Falchi adds. This high-risk population would not be expected to yield sufficient results with standard-of-care R-CHOP therapy, Falchi explains.
Epcoritamab, a bispecific antibody, has previously demonstrated efficacy in relapsed/refractory aggressive B-cell non-Hodgkin lymphomas as a single agent. Its distinct mechanism of action makes it well-suited for combination with R-CHOP.
At a median follow-up of 6.9 months, approximately 75% of patients remained on therapy and 2 patients had disease progression, Falchi concludes.